<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter" xml:lang="en">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Hematol Oncol</journal-id>
      <journal-id journal-id-type="iso-abbrev">J Hematol Oncol</journal-id>
      <journal-title-group>
        <journal-title>Journal of Hematology &amp; Oncology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1756-8722</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24011025</article-id>
      <article-id pub-id-type="pmc">3847205</article-id>
      <article-id pub-id-type="publisher-id">1756-8722-6-68</article-id>
      <article-id pub-id-type="doi">10.1186/1756-8722-6-68</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letter to the Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Leukemic transformation driven by an <italic>ASXL1</italic> mutation after a <italic>JAK2V617F</italic>-positive primary myelofibrosis: clonal evolution and hierarchy revealed by next-generation sequencing</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes" id="A1">
          <name>
            <surname>Ferrer-Mar&#xED;n</surname>
            <given-names>Francisca</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>fferrermarin@gmail.com</email>
        </contrib>
        <contrib contrib-type="author" id="A2">
          <name>
            <surname>Bellosillo</surname>
            <given-names>Beatriz</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>BBellosillo@parcdesalutmar.cat</email>
        </contrib>
        <contrib contrib-type="author" id="A3">
          <name>
            <surname>Mart&#xED;nez-Avil&#xE9;s</surname>
            <given-names>Luz</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>LMartinezAviles@parcdesalutmar.cat</email>
        </contrib>
        <contrib contrib-type="author" id="A4">
          <name>
            <surname>Soler</surname>
            <given-names>Gloria</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>gloria.soler@carm.es</email>
        </contrib>
        <contrib contrib-type="author" id="A5">
          <name>
            <surname>Carbonell</surname>
            <given-names>Pablo</given-names>
          </name>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>pablo.carbonell@carm.es</email>
        </contrib>
        <contrib contrib-type="author" id="A6">
          <name>
            <surname>Luengo-Gil</surname>
            <given-names>Gin&#xE9;s</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>gines.luengo@um.es</email>
        </contrib>
        <contrib contrib-type="author" id="A7">
          <name>
            <surname>Caparr&#xF3;s</surname>
            <given-names>Eva</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>ecp4@um.es</email>
        </contrib>
        <contrib contrib-type="author" id="A8">
          <name>
            <surname>Torregrosa</surname>
            <given-names>Jos&#xE9; M</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>josemigueltorregrosadiaz@yahoo.es</email>
        </contrib>
        <contrib contrib-type="author" id="A9">
          <name>
            <surname>Besses</surname>
            <given-names>Carlos</given-names>
          </name>
          <xref ref-type="aff" rid="I4">4</xref>
          <email>cbesses@parcdesalutmar.cat</email>
        </contrib>
        <contrib contrib-type="author" id="A10">
          <name>
            <surname>Vicente</surname>
            <given-names>Vicente</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>vicente.vicente@carm.es</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Hematology and Medical Oncology Unit, Hospital Universitario Morales-Meseguer, Centro Regional de Hemodonaci&#xF3;n, C/Ronda de Garay, sn. 3003, Murcia, Spain</aff>
      <aff id="I2"><label>2</label>Department of Pathology, Hospital del Mar-IMIM, Barcelona, Spain</aff>
      <aff id="I3"><label>3</label>Molecular Genetics Unit, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain</aff>
      <aff id="I4"><label>4</label>Department of Hematology, Hospital del Mar-IMIM, Barcelona, Spain</aff>
      <pub-date pub-type="collection">
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>8</day>
        <month>9</month>
        <year>2013</year>
      </pub-date>
      <volume>6</volume>
      <fpage>68</fpage>
      <lpage>68</lpage>
      <history>
        <date date-type="received">
          <day>1</day>
          <month>9</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>3</day>
          <month>9</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2013 Ferrer-Mar&#xED;n et al.; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2013</copyright-year>
        <copyright-holder>Ferrer-Mar&#xED;n et al.; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://www.jhoonline.org/content/6/1/68"/>
      <abstract>
        <p>We have characterized the molecular changes underlying the transformation of a <italic>JAK2V617F</italic><sup>+</sup>-myelofibrosis with trisomy 8, into a <italic>JAK2V617F</italic>-negative leukemia. Leukemic clone did not carry <italic>JAK2V617F</italic> mutation, but showed <italic>ASXL1</italic> mutation (R693X). This mutation was identified in a low percentage at diagnosis by next-generation sequencing. Using this technology in serial specimens during the follow-up, we observed a progressive expansion of the <italic>ASXL1</italic>-mutated minor clone, whereas the <italic>JAK2V617F</italic><sup>+</sup>-clone carrying trisomy 8 decreased. Hematologic progression occurred simultaneously with an <italic>ASXL1</italic>-R693X-negative lung-cancer. This is the first report showing a clear association between the expansion of an <italic>ASXL1</italic>-mutated clone and the leukemic transformation of myelofibrosis.</p>
      </abstract>
      <kwd-group>
        <kwd>Myelofibrosis</kwd>
        <kwd>
          <italic>ASXL1</italic>
        </kwd>
        <kwd>Gene mutations</kwd>
        <kwd>Acute myeloid leukemia</kwd>
        <kwd>Clonality</kwd>
        <kwd>Next-generation sequencing</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Letters to the editor</title>
      <p>It is known that patients with <italic>JAK2V617F</italic><sup><italic>+</italic></sup> myeloproliferative neoplasms (MPNs) can progress to a <italic>JAK2V617F&#xAF;</italic> acute myeloid leukemia (AML)
[<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref>]. These two phases of the disease may represent two different clones
[<xref ref-type="bibr" rid="B1">1</xref>], however, the time-dependent clonal hierarchy is just beginning to be elucidated
[<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>].</p>
      <p><italic>ASXL1</italic> is the second most frequently mutated gene after <italic>JAK2</italic> (~34.5%) in myelofibrosis (MF)
[<xref ref-type="bibr" rid="B6">6</xref>]. <italic>ASXL1</italic> mutations are also found in solid neoplasms and all types of myeloid malignancies
[<xref ref-type="bibr" rid="B7">7</xref>]. They are associated with aggressive disease
[<xref ref-type="bibr" rid="B8">8</xref>] but their role in leukemic transformation remains controversial. <italic>ASXL1</italic> mutations correlated with progression to blast-state in myelodysplastic syndromes and chronic myelomonocytic leukaemia
[<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>] while in MF, they are detectable in most patients at diagnosis
[<xref ref-type="bibr" rid="B11">11</xref>], and they are present in chronic- and blast-phases
[<xref ref-type="bibr" rid="B2">2</xref>] with the same prevalence
[<xref ref-type="bibr" rid="B6">6</xref>]. These findings suggest that <italic>ASXL1</italic> mutations play a crucial role in the pathogenesis of MF
[<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B11">11</xref>] but they do not directly cause a leukemic phenotype
[<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B6">6</xref>]. We here characterize the molecular changes associated to the leukemic transformation of a patient with primary-MF (PMF) using next-generation sequencing (NGS). By the time of the hematologic progression, the patient also developed a lung adenocarcinoma. The relationship between the clonal hierarchy and phenotype disease over time are discussed.</p>
    </sec>
    <sec>
      <title>Case presentation</title>
      <p>A 62-year-old male with 126 pack-year smoking history, cardiomyopathy and chronic-pulmonary disease was referred to our Department in May&#x2019; 2007 for evaluation of anemia, splenomegaly and fever. Following a peripheral blood (PB) and a bone marrow (BM) examination, a diagnosis of PMF according to WHO criteria was made, IPSS intermediate-2
[<xref ref-type="bibr" rid="B12">12</xref>]. Genetic analysis revealed a trisomy 8 in all 18 metaphases analyzed and the <italic>JAK2V617F</italic> mutation. With hydroxyurea, the patient achieved a complete resolution of fever and splenomegaly, and hemoglobin normalization. Thirty months later, he started with lumbar pain and leukocytosis (12.9 &#xD7; 10<sup>9</sup>/L). A new BM biopsy showed severe fibrosis with osteosclerosis. Due to the patients&#x2019;s comorbidities, allogeneic transplant was not possible and hydroxyurea was continued. In December&#x2019; 2010, the patient developed fever, splenomegaly, marked leukocytosis (81.3 &#xD7; 10<sup>9</sup>/L) and required red-cell transfusions. A new BM biopsy confirmed leukemic transformation (Figure&#xA0;
<xref ref-type="fig" rid="F1">1</xref>A) but fluorescence <italic>in situ</italic> hybridization (FISH) analysis discarded trisomy 8. Hydroxyurea was increased achieving a good control of leukocyte count. Few weeks later, he began with back and thoracic pain. A computed tomography (CT) scan revealed a speculated right lung nodule (Figure&#xA0;
<xref ref-type="fig" rid="F1">1</xref>B). Biopsy confirmed non&#x2013;small-cell lung cancer (NSCLC) (T1N0MX) and a PET-CT for staging was made (Figure&#xA0;
<xref ref-type="fig" rid="F1">1</xref>C). Despite starting treatment for AML with thioguanine, the patient died because of acute congestive heart and liver failure. A post-mortem liver biopsy uncovered metastatic infiltration by NSCLC.</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p><bold>Histologic and radiologic studies at the time of leukemic transformation. (A)</bold> BM biopsy showing immature myeloid proliferation without segmentation (blasts &gt;20%) and dysplastic megakaryocytes. With silver staining (right panel), marked reticulin fibrosis associated with osteoesclerosis was also shown. <bold>(B)</bold> Chest CT scan showing an increase in bone density of the vertebral bodies and a right lung nodule of 2 &#xD7; 2&#xA0;cm in size with speculated edges. <bold>(C)</bold> Positron-emission tomography with CT showing a markedly increased of <sup>18</sup>&#x2009;F-FDG uptake in the BM of the vertebral bodies; sacrum; extremity bones (specially left humerus); and focal in the spleen.</p>
        </caption>
        <graphic xlink:href="1756-8722-6-68-1"/>
      </fig>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>To further investigate the molecular mechanisms underlying neoplastic progression in this case, we performed <italic>JAK2V617F</italic> allele burden in PB granulocytes obtained at three time points, by allele-specific qRT-PCR
[<xref ref-type="bibr" rid="B13">13</xref>]. <italic>JAK2V617F</italic> allele percentage decreased from 30% at diagnosis to undetectable level at blast-phase with an intermediate value of 20% (Figure&#xA0;
<xref ref-type="fig" rid="F2">2</xref>A). A clonal analysis with microsatellites for 4 markers on chromosome 9p flanking <italic>JAK2,</italic> on PB granulocytes taken at diagnosis and in the blast-phase,
[<xref ref-type="bibr" rid="B14">14</xref>] did not show loss of heterozygosity on chromosome 9p (9pLOH), either at diagnosis (<italic>JAK2V617F</italic><sup><italic>+</italic></sup>-clone) or at blast-stage (dominant <italic>JAK2V617F&#xAF;</italic>-clone) (Figure&#xA0;
<xref ref-type="fig" rid="F2">2</xref>B), suggesting that at presentation, two independent clones were likely present in our patient. To address this question, sequencing of <italic>ASXL1</italic> (exon 12), <italic>TET2</italic> (all exons), <italic>TP53</italic> (exon 4&#x2013;9), <italic>IDH1</italic> (R132), <italic>IDH2</italic> (R140, R172), <italic>c-CBL</italic> (exons 8&#x2013;9) by Sanger and <italic>SRSF2</italic> (exon 1), <italic>SF3B1</italic> (exons 14&#x2013;15) by NGS (454-GS Junior platform) were performed, in the same samples, as described
[<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>]. At blast-phase, we identified an <italic>ASXL1</italic>-nonsense mutation (R693X), which was not present at diagnosis either by conventional sequencing (Figure&#xA0;
<xref ref-type="fig" rid="F2">2</xref>C) or by high resolution melting analysis (not shown). However, by using NGS (sensibility 1%,
[<xref ref-type="bibr" rid="B17">17</xref>]) we were able to detect the <italic>ASXL1</italic>-R693X mutation at diagnosis in a very low level (2%). Additionally, using NGS at two time-points during follow-up, we observed an expansion of the <italic>ASXL1</italic>-R693X subclone, with a maximum value of 50% at blast-phase (Figure&#xA0;
<xref ref-type="fig" rid="F2">2</xref>A).</p>
      <fig id="F2" position="float">
        <label>Figure 2</label>
        <caption>
          <p><bold>Clonal progression from diagnosis of PMF to leukemic transformation and death. (A)</bold> Dynamic changes in the size of the two mutated clones, <italic>JAK2V617F</italic> and <italic>ASXL1</italic>-R693X, in three time points during follow up: at the time of presentation of PMF, during the evolution and in blast-phase. <bold>(B)</bold> Microsatellite analysis on PB granulocytes at diagnosis (left panel) and blast-phase of MF (right panel) for 4 markers on chromosome 9p flanking JAK2. The positions of microsatellite markers used to identify the common 9pLOH region are shown as vertical lines <bold>(C)</bold> ASXL1 sequencing in paired samples of cDNA from PB granulocytes showing one nonsense mutation (R693X) in the <italic>ASXL1</italic> gene at blast-phase, but not at diagnosis (left panel). This mutation was not detected in the hepatic metastatic tissue of lung cancer (right panel).</p>
        </caption>
        <graphic xlink:href="1756-8722-6-68-2"/>
      </fig>
      <p>Since <italic>ASXL1</italic> has been involved in epithelial malignancy tumorigenesis
[<xref ref-type="bibr" rid="B18">18</xref>] and cancer
[<xref ref-type="bibr" rid="B7">7</xref>], we sequenced <italic>ASXL1</italic> gene in the hepatic metastatic tissue of lung cancer, but <italic>ASXL1</italic>-R693X mutation was not detected (Figure&#xA0;
<xref ref-type="fig" rid="F2">2</xref>C), suggesting that at least three malignant clones might be present.</p>
      <p>Overall, in this patient, at early disease, the PMF phenotype was driven mainly by a <italic>JAK2V617F</italic><sup><italic>+</italic></sup>-dominant clone carrying trisomy 8. During the evolution this clone declined, whereas the <italic>ASXL1</italic>-mutated minor clone expanded, promoting the progression to leukemia. The reasons for these gradual shifts are unknown. Although hydroxyurea may induce a decrease in <italic>JAK2V617F</italic> allele burden in <italic>JAK2V617F</italic><sup><italic>+</italic></sup>-MPNs
[<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B19">19</xref>], leukemic transformation in MF can occur without any prior therapy
[<xref ref-type="bibr" rid="B20">20</xref>]. Furthermore, <italic>ASXL1</italic>-R693X mutation, as other mutations affecting genes with epigenetic role, likely favor the occurrence of secondary genetic events and, in association with other cooperating mutations, promotes blast-crisis
[<xref ref-type="bibr" rid="B5">5</xref>].</p>
      <p>The molecular mechanisms undergoing the myeloid leukemogenesis promoted by <italic>ASXL1</italic> have been recently reported
[<xref ref-type="bibr" rid="B21">21</xref>], but in MF, the role of <italic>ASXL1</italic> mutations in leukemic transformation is still unclear
[<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B22">22</xref>]. By using NGS, we report, for the first time, an association between expansion of an <italic>ASXL1</italic>-mutated clone and MF progression to AML suggesting that in MF, as in other myeloid malignancies, <italic>ASXL1</italic> mutations play a role in leukemic transformation. Given the prevalence of <italic>ASXL1</italic> mutations in patients with MF, determination of <italic>ASXL1</italic> mutation status in these patients could help in the molecular disease monitoring.</p>
    </sec>
    <sec>
      <title>Consent</title>
      <p>Written informed consent was obtained from the next of kin of the patient for publication of this Case report. A copy of the written consent is available for review by the Editor-in-Chief of this journal.</p>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>The authors declare that they have no competing interests.</p>
    </sec>
    <sec>
      <title>Authors&#x2019; contributions</title>
      <p>FFM provided clinical information, directed the study and wrote the manuscript. BB designed experiments, analyzed the sequencing data and contributed to the manuscript. LMA performed the molecular biology studies. GS performed cytogenetic and FISH analysis. PC performed the microsatellite analysis. EC and GLG contributed to perform molecular analysis experiments. JMT carried out acquisition of data&#x2019;s patient. CB and VV supervised the study and were responsible for manuscript review. All authors have reviewed and approved the manuscript.</p>
    </sec>
  </body>
  <back>
    <sec>
      <title>Acknowledgments</title>
      <p>We thank Dr J Corral for his helpful discussions.</p>
    </sec>
    <ref-list>
      <ref id="B1">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Beer</surname>
            <given-names>PA</given-names>
          </name>
          <name>
            <surname>Delhommeau</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>LeCouedic</surname>
            <given-names>JP</given-names>
          </name>
          <name>
            <surname>Dawson</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Bareford</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Kusec</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>McMullin</surname>
            <given-names>MF</given-names>
          </name>
          <name>
            <surname>Harrison</surname>
            <given-names>CN</given-names>
          </name>
          <name>
            <surname>Vannucchi</surname>
            <given-names>AM</given-names>
          </name>
          <etal/>
          <article-title>Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm</article-title>
          <source>Blood</source>
          <year>2010</year>
          <volume>115</volume>
          <fpage>2891</fpage>
          <lpage>2900</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2009-08-236596</pub-id>
          <pub-id pub-id-type="pmid">20008300</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Abdel-Wahab</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Manshouri</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Patel</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Harris</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Yao</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Hedvat</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Heguy</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Bueso-Ramos</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Kantarjian</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Levine</surname>
            <given-names>RL</given-names>
          </name>
          <name>
            <surname>Verstovsek</surname>
            <given-names>S</given-names>
          </name>
          <article-title>Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias</article-title>
          <source>Cancer Res</source>
          <year>2010</year>
          <volume>70</volume>
          <fpage>447</fpage>
          <lpage>452</lpage>
          <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-3783</pub-id>
          <pub-id pub-id-type="pmid">20068184</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Theocharides</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Boissinot</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Girodon</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Garand</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Teo</surname>
            <given-names>SS</given-names>
          </name>
          <name>
            <surname>Lippert</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Talmant</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Tichelli</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Hermouet</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Skoda</surname>
            <given-names>RC</given-names>
          </name>
          <article-title>Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation</article-title>
          <source>Blood</source>
          <year>2007</year>
          <volume>110</volume>
          <fpage>375</fpage>
          <lpage>379</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2006-12-062125</pub-id>
          <pub-id pub-id-type="pmid">17363731</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Jager</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Kralovics</surname>
            <given-names>R</given-names>
          </name>
          <article-title>Molecular basis and clonal evolution of myeloproliferative neoplasms</article-title>
          <source>Haematologica</source>
          <year>2010</year>
          <volume>95</volume>
          <fpage>526</fpage>
          <lpage>529</lpage>
          <pub-id pub-id-type="doi">10.3324/haematol.2009.019570</pub-id>
          <pub-id pub-id-type="pmid">20378573</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Vainchenker</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Delhommeau</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Constantinescu</surname>
            <given-names>SN</given-names>
          </name>
          <name>
            <surname>Bernard</surname>
            <given-names>OA</given-names>
          </name>
          <article-title>New mutations and pathogenesis of myeloproliferative neoplasms</article-title>
          <source>Blood</source>
          <year>2011</year>
          <volume>118</volume>
          <fpage>1723</fpage>
          <lpage>1735</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2011-02-292102</pub-id>
          <pub-id pub-id-type="pmid">21653328</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Stein</surname>
            <given-names>BL</given-names>
          </name>
          <name>
            <surname>Williams</surname>
            <given-names>DM</given-names>
          </name>
          <name>
            <surname>O&#x2019;Keefe</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Rogers</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Ingersoll</surname>
            <given-names>RG</given-names>
          </name>
          <name>
            <surname>Spivak</surname>
            <given-names>JL</given-names>
          </name>
          <name>
            <surname>Verma</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Maciejewski</surname>
            <given-names>JP</given-names>
          </name>
          <name>
            <surname>McDevitt</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Moliterno</surname>
            <given-names>AR</given-names>
          </name>
          <article-title>Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes</article-title>
          <source>Haematologica</source>
          <year>2011</year>
          <volume>96</volume>
          <fpage>1462</fpage>
          <lpage>1469</lpage>
          <pub-id pub-id-type="doi">10.3324/haematol.2011.045591</pub-id>
          <pub-id pub-id-type="pmid">21712540</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Abdel-Wahab</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Dey</surname>
            <given-names>A</given-names>
          </name>
          <article-title>The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics</article-title>
          <source>Leukemia</source>
          <year>2013</year>
          <volume>27</volume>
          <fpage>10</fpage>
          <lpage>15</lpage>
          <pub-id pub-id-type="doi">10.1038/leu.2012.288</pub-id>
          <pub-id pub-id-type="pmid">23147254</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Gelsi-Boyer</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Brecqueville</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Devillier</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Murati</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Mozziconacci</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Birnbaum</surname>
            <given-names>D</given-names>
          </name>
          <article-title>Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases</article-title>
          <source>J Hematol Oncol</source>
          <year>2012</year>
          <volume>5</volume>
          <fpage>12</fpage>
          <pub-id pub-id-type="doi">10.1186/1756-8722-5-12</pub-id>
          <pub-id pub-id-type="pmid">22436456</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Thol</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Friesen</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Damm</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Yun</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Weissinger</surname>
            <given-names>EM</given-names>
          </name>
          <name>
            <surname>Krauter</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Wagner</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Chaturvedi</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Sharma</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Wichmann</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
          <article-title>Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes</article-title>
          <source>J Clin Oncol</source>
          <year>2011</year>
          <volume>29</volume>
          <fpage>2499</fpage>
          <lpage>2506</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2010.33.4938</pub-id>
          <pub-id pub-id-type="pmid">21576631</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Gelsi-Boyer</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Trouplin</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Roquain</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Adelaide</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Carbuccia</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Esterni</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Finetti</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Murati</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Arnoulet</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Zerazhi</surname>
            <given-names>H</given-names>
          </name>
          <etal/>
          <article-title>ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia</article-title>
          <source>Br J Haematol</source>
          <year>2010</year>
          <volume>151</volume>
          <fpage>365</fpage>
          <lpage>375</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2141.2010.08381.x</pub-id>
          <pub-id pub-id-type="pmid">20880116</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Ricci</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Spinelli</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Salmoiraghi</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Finazzi</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Carobbio</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Rambaldi</surname>
            <given-names>A</given-names>
          </name>
          <article-title>ASXL1 mutations in primary and secondary myelofibrosis</article-title>
          <source>Br J Haematol</source>
          <year>2012</year>
          <volume>156</volume>
          <fpage>404</fpage>
          <lpage>407</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2141.2011.08865.x</pub-id>
          <pub-id pub-id-type="pmid">21923651</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Cervantes</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Dupriez</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Pereira</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Passamonti</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Reilly</surname>
            <given-names>JT</given-names>
          </name>
          <name>
            <surname>Morra</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Vannucchi</surname>
            <given-names>AM</given-names>
          </name>
          <name>
            <surname>Mesa</surname>
            <given-names>RA</given-names>
          </name>
          <name>
            <surname>Demory</surname>
            <given-names>JL</given-names>
          </name>
          <name>
            <surname>Barosi</surname>
            <given-names>G</given-names>
          </name>
          <etal/>
          <article-title>New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment</article-title>
          <source>Blood</source>
          <year>2009</year>
          <volume>113</volume>
          <fpage>2895</fpage>
          <lpage>2901</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2008-07-170449</pub-id>
          <pub-id pub-id-type="pmid">18988864</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Besses</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Alvarez-Larran</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Martinez-Aviles</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Mojal</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Longaron</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Salar</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Florensa</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Serrano</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Bellosillo</surname>
            <given-names>B</given-names>
          </name>
          <article-title>Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients</article-title>
          <source>Br J Haematol</source>
          <year>2011</year>
          <volume>152</volume>
          <fpage>413</fpage>
          <lpage>419</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2141.2010.08467.x</pub-id>
          <pub-id pub-id-type="pmid">21219298</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Kralovics</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Passamonti</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Buser</surname>
            <given-names>AS</given-names>
          </name>
          <name>
            <surname>Teo</surname>
            <given-names>SS</given-names>
          </name>
          <name>
            <surname>Tiedt</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Passweg</surname>
            <given-names>JR</given-names>
          </name>
          <name>
            <surname>Tichelli</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Cazzola</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Skoda</surname>
            <given-names>RC</given-names>
          </name>
          <article-title>A gain-of-function mutation of JAK2 in myeloproliferative disorders</article-title>
          <source>N Engl J Med</source>
          <year>2005</year>
          <volume>352</volume>
          <fpage>1779</fpage>
          <lpage>1790</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa051113</pub-id>
          <pub-id pub-id-type="pmid">15858187</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Martinez-Aviles</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Besses</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Alvarez-Larran</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Torres</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Serrano</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Bellosillo</surname>
            <given-names>B</given-names>
          </name>
          <article-title>TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms</article-title>
          <source>Ann Hematol</source>
          <year>2012</year>
          <volume>91</volume>
          <fpage>533</fpage>
          <lpage>541</lpage>
          <pub-id pub-id-type="doi">10.1007/s00277-011-1330-0</pub-id>
          <pub-id pub-id-type="pmid">21904853</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B16">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Martinez-Aviles</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Alvarez-Larran</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Besses</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Navarro</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Torres</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Longaron</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Angona</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Pedro</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Florensa</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Serrano</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Bellosillo</surname>
            <given-names>B</given-names>
          </name>
          <article-title>Clinical significance of clonality assessment in JAK2V617F-negative essential thrombocythemia</article-title>
          <source>Ann Hematol</source>
          <year>2012</year>
          <volume>91</volume>
          <fpage>1555</fpage>
          <lpage>1562</lpage>
          <pub-id pub-id-type="doi">10.1007/s00277-012-1502-6</pub-id>
          <pub-id pub-id-type="pmid">22706669</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B17">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Pietra</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Brisci</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Rumi</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Boggi</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Elena</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Pietrelli</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Bordoni</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Ferrari</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Passamonti</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>De Bellis</surname>
            <given-names>G</given-names>
          </name>
          <etal/>
          <article-title>Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms</article-title>
          <source>Haematologica</source>
          <year>2011</year>
          <volume>96</volume>
          <fpage>607</fpage>
          <lpage>611</lpage>
          <pub-id pub-id-type="doi">10.3324/haematol.2010.034793</pub-id>
          <pub-id pub-id-type="pmid">21228032</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B18">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Scotto</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Narayan</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Nandula</surname>
            <given-names>SV</given-names>
          </name>
          <name>
            <surname>Arias-Pulido</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Subramaniyam</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Schneider</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Kaufmann</surname>
            <given-names>AM</given-names>
          </name>
          <name>
            <surname>Wright</surname>
            <given-names>JD</given-names>
          </name>
          <name>
            <surname>Pothuri</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Mansukhani</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Murty</surname>
            <given-names>VV</given-names>
          </name>
          <article-title>Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: potential role in progression</article-title>
          <source>Genes Chromosomes Cancer</source>
          <year>2008</year>
          <volume>47</volume>
          <fpage>755</fpage>
          <lpage>765</lpage>
          <pub-id pub-id-type="doi">10.1002/gcc.20577</pub-id>
          <pub-id pub-id-type="pmid">18506748</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B19">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Girodon</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Schaeffer</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Cleyrat</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Mounier</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Lafont</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Santos</surname>
            <given-names>FD</given-names>
          </name>
          <name>
            <surname>Duval</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Maynadie</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Hermouet</surname>
            <given-names>S</given-names>
          </name>
          <article-title>Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy</article-title>
          <source>Haematologica</source>
          <year>2008</year>
          <volume>93</volume>
          <fpage>1723</fpage>
          <lpage>1727</lpage>
          <pub-id pub-id-type="doi">10.3324/haematol.13081</pub-id>
          <pub-id pub-id-type="pmid">18728027</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B20">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Bjorkholm</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Derolf</surname>
            <given-names>AR</given-names>
          </name>
          <name>
            <surname>Hultcrantz</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Kristinsson</surname>
            <given-names>SY</given-names>
          </name>
          <name>
            <surname>Ekstrand</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Goldin</surname>
            <given-names>LR</given-names>
          </name>
          <name>
            <surname>Andreasson</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Birgegard</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Linder</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Malm</surname>
            <given-names>C</given-names>
          </name>
          <etal/>
          <article-title>Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms</article-title>
          <source>J Clin Oncol</source>
          <year>2011</year>
          <volume>29</volume>
          <fpage>2410</fpage>
          <lpage>2415</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2011.34.7542</pub-id>
          <pub-id pub-id-type="pmid">21537037</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B21">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Abdel-Wahab</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Adli</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>LaFave</surname>
            <given-names>LM</given-names>
          </name>
          <name>
            <surname>Gao</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Hricik</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Shih</surname>
            <given-names>AH</given-names>
          </name>
          <name>
            <surname>Pandey</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Patel</surname>
            <given-names>JP</given-names>
          </name>
          <name>
            <surname>Chung</surname>
            <given-names>YR</given-names>
          </name>
          <name>
            <surname>Koche</surname>
            <given-names>R</given-names>
          </name>
          <etal/>
          <article-title>ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression</article-title>
          <source>Cancer Cell</source>
          <year>2012</year>
          <volume>22</volume>
          <fpage>180</fpage>
          <lpage>193</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ccr.2012.06.032</pub-id>
          <pub-id pub-id-type="pmid">22897849</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B22">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Vannucchi</surname>
            <given-names>AM</given-names>
          </name>
          <name>
            <surname>Lasho</surname>
            <given-names>TL</given-names>
          </name>
          <name>
            <surname>Guglielmelli</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Biamonte</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Pardanani</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Pereira</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Finke</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Score</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Gangat</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Mannarelli</surname>
            <given-names>C</given-names>
          </name>
          <etal/>
          <article-title>Mutations and prognosis in primary myelofibrosis</article-title>
          <source>Leukemia</source>
          <year>2013</year>
          <volume>27</volume>
          <fpage>1861</fpage>
          <lpage>1869</lpage>
          <pub-id pub-id-type="doi">10.1038/leu.2013.119</pub-id>
          <pub-id pub-id-type="pmid">23619563</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
